Mirum ex­pands la­bel for rare liv­er dis­ease drug, serv­ing up more com­pe­ti­tion for Ipsen's Byl­vay

The FDA on Wednes­day ex­pand­ed the ap­proval of Mirum Phar­ma­ceu­ti­cals’ Liv­mar­li (mar­al­ix­i­bat) for the treat­ment of in­tense itch­ing re­lat­ed to a rare liv­er dis­ease in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER